Abstract
The role of Helicobacter pylori in peptic-disease, gastric adeno-carcinoma and the MALT- lymphoma is established. The H. pylori diagnostics and the eradication therapy are highly disputed in patients with dyspepsia. An endoscopy is recommended to patients older than 45 who have dyspeptic disorders. Non-invasive testing and treatment is an adequate option to those patients younger than 45, if no alarm symptoms exist. The H.pylori serology, the 13C- breath test and the stool-antigen test have proven to be the best in laboratory testing. The therapeutic regimen of H. pylori eradication consists of a proton pump inhibitor (PPI) and two antibiotics, though it isn't always successful. After a second treatment failure, a H. pylori culture is indicated to asses the antibiotic resistances.
MeSH terms
-
Adenocarcinoma / diagnosis*
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / pathology
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Ulcer Agents / therapeutic use
-
Diagnosis, Differential
-
Drug Therapy, Combination
-
Gastric Mucosa / microbiology
-
Gastric Mucosa / pathology
-
Gastritis / diagnosis*
-
Gastritis / drug therapy
-
Gastritis / pathology
-
Helicobacter Infections / diagnosis*
-
Helicobacter Infections / drug therapy
-
Helicobacter Infections / pathology
-
Helicobacter pylori* / pathogenicity
-
Humans
-
Lymphoma, B-Cell, Marginal Zone / diagnosis*
-
Lymphoma, B-Cell, Marginal Zone / drug therapy
-
Lymphoma, B-Cell, Marginal Zone / pathology
-
Peptic Ulcer / diagnosis*
-
Peptic Ulcer / drug therapy
-
Peptic Ulcer / pathology
-
Proton Pump Inhibitors
-
Stomach Neoplasms / diagnosis*
-
Stomach Neoplasms / drug therapy
-
Stomach Neoplasms / pathology
-
Virulence
Substances
-
Anti-Bacterial Agents
-
Anti-Ulcer Agents
-
Proton Pump Inhibitors